Abstract
Drug-target Mendelian randomization (MR) is a popular approach for exploring the effects of pharmacological targets. Cis-MR designs select variants within the gene region that code for a protein of interest to mimic pharmacological perturbation. An alternative uses variants associated with behavioral proxies of target perturbation, such as drug usage. Both have been employed to investigate the effects of caffeine but have drawn different conclusions. We use the effects of caffeine on body mass index (BMI) as a case study to highlight two potential flaws of the latter strategy in drug-target MR: misidentifying the exposure and using invalid instruments. Some variants associate with caffeine consumption because of their role in caffeine metabolism. Since people with these variants require less caffeine for the same physiological effect, the direction of the caffeine-BMI association is flipped depending on whether estimates are scaled by caffeine consumption or plasma caffeine levels. Other variants seem to associate with caffeine consumption via behavioral pathways. Using multivariable-MR, we demonstrate that caffeine consumption behavior influences BMI independently of plasma caffeine. This implies the existence of behaviorally mediated exclusion restriction violations. Our results support the superiority of cis-MR study designs in pharmacoepidemiology over the use of behavioral proxies of drug targets.
Competing Interest Statement
B.W. and T.C. performed statistical analysis. B.W. wrote the first draft of the manuscript. All authors contributed to the design of the study and edited the manuscript for intellectual content.
Funding Statement
B.W. is funded by an Economic and Social Research Council (ESRC) South West Doctoral Training Partnership (SWDTP) 1 + 3 PhD Studentship Award (ES/P000630/1) and a is member of the Medical Research Council (MRC) Integrative Epidemiology Unit at the University of Bristol (MC_UU_00011/7). D.G. is supported by the British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College. S.C.L. is supported by the Swedish Research Council for Health, Working Life and Welfare (Forte, 2018-00123), Swedish Heart Lung Foundation (Hjart-Lungfonden, 20210351), and Swedish Research Council (Vetenskapsradet, 2019-00977).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
OpenGWAS project or GWAS original publications.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online.
